Rainer Strohmenger
Metropolregion München
13.472 Follower:innen
500+ Kontakte
Artikel von Rainer Strohmenger
-
5th successful trade sale exit for Wellington Partners Life Science within 12 months
5th successful trade sale exit for Wellington Partners Life Science within 12 months
Von Rainer Strohmenger
Aktivitäten
-
#LISAEventTip: BIOTECH SUMMIT AUSTRIA 2024 Join us this October in Innsbruck as the national and international #biotech community gathers! This…
#LISAEventTip: BIOTECH SUMMIT AUSTRIA 2024 Join us this October in Innsbruck as the national and international #biotech community gathers! This…
Beliebt bei Rainer Strohmenger
-
In 2000, Harpreet co-founded a venture after his PhD. Now, Immatics is one of the 15 most valuable European biotechs. Great to meet him in person…
In 2000, Harpreet co-founded a venture after his PhD. Now, Immatics is one of the 15 most valuable European biotechs. Great to meet him in person…
Beliebt bei Rainer Strohmenger
-
NPR 1A podcast invited our CEO Michael Curtis to join a discussion to discuss the current state of #kidney transplantation and what the future might…
NPR 1A podcast invited our CEO Michael Curtis to join a discussion to discuss the current state of #kidney transplantation and what the future might…
Beliebt bei Rainer Strohmenger
Berufserfahrung
Ausbildung
-
–
Activities and Societies: Studies in human medicine (3. Staatsexamen), M.D. Experimental research at the Institute of Physiology at the LMU Munich to obtain the title "Dr. med." (1990-1994)
In vitro studies on the microrheological properties of whole blood in the presence of 5'-ADP and endothelial autacoids
-
–
Veröffentlichungen
-
Adverse selection and categorical discrimination in health insurance markets: The effects of genetic testing
Journal of Health Economics 19, 197-218 (2000)
In this paper, the effects of new methods for risk classification, e.g., genetic tests, on health insurance markets are studied using an insurance model with state contingent utility functions. The analysis focuses on the case of treatment costs higher than the patient's willingness to pay where standard models of asymmetric information are not applicable. In this case, the benefit from signing a fair insurance contract will be positive only if illness probability is low. In contrast to the…
In this paper, the effects of new methods for risk classification, e.g., genetic tests, on health insurance markets are studied using an insurance model with state contingent utility functions. The analysis focuses on the case of treatment costs higher than the patient's willingness to pay where standard models of asymmetric information are not applicable. In this case, the benefit from signing a fair insurance contract will be positive only if illness probability is low. In contrast to the common perception, additional risk classification under symmetric information can be efficiency enhancing. Under asymmetric information about illness risks, however, there can be complete market failure.
Andere Autor:innenVeröffentlichung anzeigen
Auszeichnungen/Preise
-
2nd Price, German National Competition in Mathematics 1985
German Federal Ministry of Education and Research
-
VAC Award 1997
ALUMNI organization of economists at Ludwig-Maximilian-University of Munich
Award for the best exam at the faculty of economics in 1997
Sprachen
-
German
Muttersprache oder zweisprachig
-
English
Fließend
-
French
Gute Kenntnisse
Organisationen
-
BVMW - The German Association for Small and Medium-sized Businesses
Member of the Senate
–Heute -
Invest Europe (formerly EVCA - European Private Equity & Venture Capital Association)
Member of the Venture Capital Council
–Heute
Weitere Aktivitäten von Rainer Strohmenger
-
Here’s the full press conference link…the heart is too full to tell. The future is bright.
Here’s the full press conference link…the heart is too full to tell. The future is bright.
Beliebt bei Rainer Strohmenger
-
The Washington Post covers our landmark surgery: The pig kidney was specially engineered by researchers at the Cambridge, Mass., biotechnology…
The Washington Post covers our landmark surgery: The pig kidney was specially engineered by researchers at the Cambridge, Mass., biotechnology…
Beliebt bei Rainer Strohmenger
-
Advances in the development of novel treatment options for patients requiring an #organtransplant continue to push the boundaries of medical…
Advances in the development of novel treatment options for patients requiring an #organtransplant continue to push the boundaries of medical…
Beliebt bei Rainer Strohmenger
-
Excited to share a major medical milestone today, as we announce the first ever #transplantation of a genetically engineered porcine #kidney into a…
Excited to share a major medical milestone today, as we announce the first ever #transplantation of a genetically engineered porcine #kidney into a…
Beliebt bei Rainer Strohmenger
-
A historic medical achievement was published in New York Times today. Congratulations to the team at our portfolio company…
A historic medical achievement was published in New York Times today. Congratulations to the team at our portfolio company…
Geteilt von Rainer Strohmenger
-
Great achievement Mark Toland, Andrew Cleeland, Alan J Simonian and Caleb Moore !
Great achievement Mark Toland, Andrew Cleeland, Alan J Simonian and Caleb Moore !
Beliebt bei Rainer Strohmenger
Weitere ähnliche Profile
Weitere Mitglieder, die Rainer Strohmenger heißen
Es gibt auf LinkedIn 1 weitere Person, die Rainer Strohmenger heißt.
Weitere Mitglieder anzeigen, die Rainer Strohmenger heißen